Spotlight on Bupropion in Major Depressive Disorder

被引：0
|
作者：
Sohita Dhillon
Lily P. H. Yang
Monique P. Curran
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
CNS Drugs | 2008年 / 22卷
关键词：
Major Depressive Disorder; Sustained Release; Bupropion; Major Depressive Disorder; Escitalopram;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Bupropion is presumed to be a dopamine-noradrenaline (norepinephrine) reuptake inhibitor and is an effective antidepressant. It is available as three oral formulations: (i) bupropion immediate release (IR) [Wellbutrin®] administered three times daily; (ii) bupropion sustained release (SR) [Wellbutrin SR®] administered twice daily; and (iii) bupropion extended/modified release (XR) [Wellbutrin XL®/Wellbutrin XR®] administered once daily. All three formulations are bioequivalent in terms of systemic exposure to bupropion.
引用
收藏
页码：613 / 617
页数：4
相关论文
共 50 条
  • [21] Bupropion in the treatment of major depressive disorder in real-life practice
    Sennfelt D.A.O.
    Da Silva M.A.R.M.
    Da Silva Tavares A.P.
    [J]. Clinical Drug Investigation, 2011, 31 (Suppl 1) : 19 - 24
  • [22] Bupropion efficacy in major depressive disorder and alcohol dependence dual diagnosis
    Vasile, D.
    Sarmache, M.
    Vasile, M. L.
    Gheorghe, M. D.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S292 - S293
  • [23] Sexual function during bupropion or paroxetine treatment of major depressive disorder
    Kennedy, SH
    Fulton, KA
    Bagby, RM
    Greene, AL
    Cohen, NL
    Rafi-Tari, S
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2006, 51 (04): : 234 - 242
  • [24] The combination of duloxetine and bupropion for treatment-resistant major depressive disorder
    Papakostas, GI
    Worthington, JJ
    Iosifescu, DV
    Kinrys, G
    Burns, AM
    Fisher, LB
    Homberger, CH
    Mischoulon, D
    Fava, M
    [J]. DEPRESSION AND ANXIETY, 2006, 23 (03) : 178 - 181
  • [25] Bupropion for the treatment of major depressive disorder characterized by loss of pleasure, interest and energy
    Rush, AJ
    Wightman, DS
    Vanmeter, SA
    Hampton, KD
    Krishen, A
    Modell, JG
    Tucker, VA
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S450 - S450
  • [26] Bupropion SR augmentation strategy in mirtazapine major depressive disorder incomplete responders
    Vasile, D.
    Vasiliu, O.
    Vasile, M.
    Cretu, O.
    Ojog, D.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 197 - 197
  • [27] Bupropion modified/extended release: A guide to its use in major depressive disorder
    不详
    [J]. Drugs & Therapy Perspectives, 2009, 25 (1) : 1 - 4
  • [28] Efficacy and safety of bupropion extended release in elderly patients with major depressive disorder
    Chrzanowski, W.
    Rousseau, R.
    Hewett, K.
    Gee, M. D.
    Wightman, D.
    Richard, N. E.
    Modell, J. G.
    Goodale, E. P.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S315 - S316
  • [29] Efficacy and tolerability of bupropion in major depressive disorder associated with Parkinson's disease
    Vasile, D.
    Macovei, R. A.
    Vasiliu, O.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S322 - S323
  • [30] BUPROPION FOR MAJOR DEPRESSIVE DISORDER AND SMOKING CESSATION IN PREGNANCY: A SYSTEMATIC LITERATURE REVIEW
    Lambert, Sally
    Dunlop, Adrian J.
    [J]. DRUG AND ALCOHOL REVIEW, 2018, 37 : S43 - S44
12345